By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > Group of medical associations file suit saying price setting provisions in Inflation Reduction Act are ‘unconstitutional’
Investing

Group of medical associations file suit saying price setting provisions in Inflation Reduction Act are ‘unconstitutional’

News Room
Last updated: 2023/06/22 at 1:11 AM
By News Room
Share
2 Min Read
SHARE

A group of medical associations filed a suit in Texas Wednesday alleging that the price setting provisions in the Inflation Reduction Act are unconstitutional. The suit was brought by the National Infusion Center Association (NICA), the Global Colon Cancer Association (GCCA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) and filed in the U.S. District Court for the Western District of Texas. The statute “includes no requirement for checks and balances through public feedback and cuts off administrative and judicial review, violating the Constitution’s separation of power and due process clauses,” the groups said. And an “extreme excise “tax” to force manufacturer compliance with the government mandated price “is disproportionate to the purported offense making it an excessive fine prohibited by the Eighth Amendment,” they said. NCIA CEO Brian Nyquist said that his organization favors lower costs for patients, but noted that infusion providers have no control over the price of medications they administer. “he government price setting provisions in the IRA may inadvertently set reimbursement below acquisition cost, exacerbating existing consolidation trends and reducing our nation’s community-based infusion capacity,” Nyquist said in a statement. “This would leave patients with the hospital as their only option – which is by far the most expensive setting.”

Read the full article here

News Room June 22, 2023 June 22, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Inside America’s Race To Build The Next Generation Of AI Chips

Watch full video on YouTube

Bitcoin erases $600 billion in market value, losing its 2025 gains.

Watch full video on YouTube

How black boxes work

Watch full video on YouTube

Why bitcoin’s decline may be signaling a warning for markets

Watch full video on YouTube

Quanex Building Products Corporation (NX) Q4 2025 Earnings Call Transcript

FollowQ4: 2025-12-11 Earnings SummaryEPS of $0.83 beats by $0.31  | Revenue of $489.85M…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?